Internal Medicine : The oncolytic effects of reovirus in canine solid tumor cell lines

• IGASE Masaya

  Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753–8515, Japan

• HWANG Chung Chew

  Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi 753–8515, Japan

• COFFEY Matt

  Oncolytics Biotech Inc., Calgary, Alberta, Canada

• OKUDA Masaru

  Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753–8515, Japan Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi 753–8515, Japan

• NOGUCHI Shunsuke

  Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753–8515, Japan Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi 753–8515, Japan Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi 753–8515, Japan

• MIZUNO Takuya

  Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753–8515, Japan Laboratory of Molecular Diagnostics and Therapeutics, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi 753–8515, Japan Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi 753–8515, Japan

書誌事項

タイトル別名

• The oncolytic effects of reovirus in canine solid tumor cell lines

抄録

Oncolytic virotherapy is a new strategy for cancer treatment for humans and dogs. Reovirus has been proven to be a potent oncolytic virus in human medicine. Our laboratory has previously reported that canine mast cell tumor and canine lymphoma were susceptible to reovirus. In this study, canine solid tumor cell lines (mammary gland tumor, osteosarcoma and malignant melanoma) were tested to determine their susceptibility towards reovirus. We demonstrated that reovirus induces more than 50% cell death in three canine mammary gland tumors and one canine malignant melanoma cell line. The reovirus-induced cell death occurred via the activation of caspase 3. Ras activation has been shown to be one of the important mechanisms of reovirus-susceptibility in human cancers. However, Ras activation was not related to the reovirus-susceptibility in canine solid tumor cell lines, which was similar to reports in canine mast cell tumor and canine lymphoma. The results of this study highly suggest that canine mammary gland tumor and canine malignant melanoma are also potential candidates for reovirus therapy in veterinary oncology.

収録刊行物

• Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｖｅｔｅｒｉｎａｒｙ　Ｍｅｄｉｃａｌ　Ｓｃｉｅｎｃｅ

  Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｖｅｔｅｒｉｎａｒｙ　Ｍｅｄｉｃａｌ　Ｓｃｉｅｎｃｅ 77 (5), 541-548, 2015

  公益社団法人 日本獣医学会

キーワード

• cancer
• canine
• oncolytic virotherapy
• reovirus
• solid tumor

詳細情報

• CRID: 1390282681406627072
• NII論文ID: 130005071879
• NII書誌ID: AA10796138
• DOI: 10.1292/jvms.14-0570
• ISSN: 13477439
• ISSN: 09167250
• NDL書誌ID: 026448361
• PubMed: 25648933
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I026448361
• Web Site: https://search.jamas.or.jp/link/ui/2016026398
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可